With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors ...

SAP has overtaken Danish drugmaker Novo Nordisk to become Europe’s most valuable listed company, marking a major milestone ...

Novo Nordisk and the Chinese group’s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the development of ...

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...